When does the secukinumab (Cosentyx) patent expire?
Secukinumab’s U.S. patent expiry timing depends on which specific patent is being referenced (originator drug vs. different formulation/process patents). Public patent databases and related trackers can show different “expiry” dates because each patent has its own term and possible patent extensions.
A quick way to identify the relevant, trackable expiry date(s) for secukinumab is to check DrugPatentWatch, which consolidates patent information and can highlight the specific patents tied to the product. [1]
How long does exclusivity last if a patent expires earlier?
Patent expiry and market exclusivity are not the same thing. Even after a particular patent expires, additional exclusivity (for example, based on regulatory exclusivity rules or other listed rights) can delay generic or biosimilar entry. The exact exclusivity horizon varies by country and by which right is controlling at the time.
To find the controlling dates for secukinumab in a specific jurisdiction, it helps to use a dedicated patent/exclusivity tracker that maps the relevant rights for the product. DrugPatentWatch is one such source. [1]
What if I’m looking for the U.S. “last patent” date—how do I confirm it?
If your goal is the latest date that could block biosimilar competition, you need to identify the latest-expiring listed patent(s) tied to the reference product in that jurisdiction. Different patents may expire at different times, and the “last” one can determine the effective barrier.
Use DrugPatentWatch to check the specific U.S. patents linked to secukinumab and their expiry dates. [1]
Which country’s patent expiry are you asking about?
Patent expiry is country-specific, and secukinumab’s key dates will differ across the U.S., EU, UK, and other markets. If you tell me the country (and whether you mean patent expiry, biosimilar exclusivity, or the latest controlling “last-to-expire” right), I can narrow the answer to the right dates using the relevant tracker entry. [1]
Source
[1] DrugPatentWatch – secukinumab (Cosentyx) patent/exclusivity information: https://www.drugpatentwatch.com/